ARCHIVES

In Brief: Litton Bionetic’s New contract For Operation of FCRC Total $128.8 Million For Five Years

This article is from The Cancer Letter archive.

Vol. 03 No. 40 | October 7, 1977

Download PDF Visit The Full Archive

Related Articles

FDA Nearly Wrecks NCI Drug Distribution Program, Finally Agrees To New Guidelines

January 30, 1976

Ending Breast Cancer by 2020? NBCC President Fran Visco Discusses the Goal

January 25, 2013

Science Policy: All’s Well In Access to Trials, GAO Study Finds; NIH Disagrees

November 5, 1999

U.S. Tobacco Program Loses $505 il. In Loan Principle, Report Finds

January 12, 1990

FDA Says ImClone Data Insufficient To Evaluate Colorectal Cancer Drug C225.

January 4, 2002

Trial Data: No Benefit In Adding Perifosine to Capecitabine

June 29, 2012